Sort   by:  
 Page size 
UnknownNovel heterozygous variants in the EP300 gene cause Rubinstein-Taybi syndrome 2: Reports from two Chinese children.
Not available
S-EPMC10496081 | biostudies-literature
UnknownCombination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Not available
S-EPMC8541958 | biostudies-literature
UnknownPhase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.
Not available
S-EPMC11643086 | biostudies-literature
UnknownEmerging Trends in Immunotherapy for Adult Sarcomas.
Not available
S-EPMC10166169 | biostudies-literature
Unknownα-Ketoglutarate links p53 to cell fate during tumour suppression.
Not available
S-EPMC6830448 | biostudies-literature
UnknownDiverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.
Not available
S-EPMC7340310 | biostudies-literature
UnknownQuantitative and functional interrogation of parent-of-origin allelic expression biases in the brain.
Not available
S-EPMC4512258 | biostudies-literature
UnknownPreclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models
Not available
S-EPMC12127203 | biostudies-literature
UnknownIpatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.
Not available
S-EPMC12906895 | biostudies-literature
UnknownPhase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Not available
S-EPMC7367548 | biostudies-literature
Sort   by:  
 Page size